loading
Precedente Chiudi:
$134.96
Aprire:
$134.98
Volume 24 ore:
1.96M
Relative Volume:
2.10
Capitalizzazione di mercato:
$13.71B
Reddito:
$2.24B
Utile/perdita netta:
$385.90M
Rapporto P/E:
72.81
EPS:
1.86
Flusso di cassa netto:
$440.10M
1 W Prestazione:
+6.88%
1M Prestazione:
+9.84%
6M Prestazione:
+1.01%
1 anno Prestazione:
+12.56%
Intervallo 1D:
Value
$134.12
$137.01
Intervallo di 1 settimana:
Value
$127.34
$140.00
Portata 52W:
Value
$110.95
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Nome
Neurocrine Biosciences Inc
Name
Telefono
(858) 617-7600
Name
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Dipendente
1,700
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
135.42 13.71B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
164.84 74.37B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.69 43.81B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.10 41.53B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
22.09 25.03B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
12.52 14.94B 15.05B -883.30M 1.89B -0.74

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-10 Ripresa Raymond James Outperform
2024-08-29 Aggiornamento Piper Sandler Neutral → Overweight
2024-04-24 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-13 Ripresa Citigroup Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-21 Reiterato Mizuho Neutral
2023-07-24 Aggiornamento SVB Securities Market Perform → Outperform
2023-07-06 Aggiornamento BMO Capital Markets Underperform → Market Perform
2023-05-04 Aggiornamento Guggenheim Neutral → Buy
2023-03-30 Aggiornamento Canaccord Genuity Hold → Buy
2023-03-03 Aggiornamento Evercore ISI In-line → Outperform
2023-02-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-11-14 Downgrade Evercore ISI Outperform → In-line
2022-10-11 Iniziato UBS Buy
2022-09-26 Iniziato Wells Fargo Equal Weight
2022-06-06 Ripresa Jefferies Buy
2022-03-03 Downgrade Piper Sandler Overweight → Neutral
2022-02-25 Aggiornamento Goldman Neutral → Buy
2022-01-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Iniziato BMO Capital Markets Underperform
2021-11-17 Aggiornamento JP Morgan Neutral → Overweight
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-08-06 Downgrade Canaccord Genuity Buy → Hold
2021-05-18 Ripresa Goldman Neutral
2021-05-06 Aggiornamento Barclays Equal Weight → Overweight
2021-02-02 Iniziato Raymond James Outperform
2020-09-30 Iniziato The Benchmark Company Hold
2020-08-04 Downgrade JP Morgan Overweight → Neutral
2020-06-29 Downgrade Goldman Buy → Neutral
2020-06-09 Iniziato Wedbush Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-27 Iniziato Barclays Equal Weight
2020-02-24 Iniziato William Blair Outperform
2020-02-06 Iniziato Mizuho Neutral
2020-02-05 Reiterato H.C. Wainwright Buy
2019-12-13 Downgrade Credit Suisse Outperform → Neutral
2019-08-07 Iniziato RBC Capital Mkts Outperform
2019-07-16 Iniziato Oppenheimer Outperform
2019-06-05 Iniziato Guggenheim Neutral
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-22 Aggiornamento JP Morgan Neutral → Overweight
2019-04-12 Iniziato Evercore ISI Outperform
2019-02-06 Reiterato BofA/Merrill Buy
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-12-13 Iniziato Goldman Buy
2018-11-21 Iniziato Canaccord Genuity Buy
Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
03:17 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

03:17 AM
pulisher
Dec 20, 2024

What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter

Dec 20, 2024
pulisher
Dec 20, 2024

Needham & Company LLC Reaffirms "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire

Dec 20, 2024
pulisher
Dec 19, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Neurocrine Biosciences chief regulatory officer sells $147,285 in shares - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Neurocrine Biosciences chief regulatory officer sells $147,285 in shares By Investing.com - Investing.com UK

Dec 19, 2024
pulisher
Dec 18, 2024

Neurocrine Biosciences' SWOT analysis: stock outlook mixed amid pipeline setbacks - Investing.com Canada

Dec 18, 2024
pulisher
Dec 18, 2024

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha

Dec 18, 2024
pulisher
Dec 18, 2024

Tidal Investments LLC Acquires 5,197 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

HighTower Advisors LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Neurocrine wins FDA OK for first-in-class CAH drug - The Pharma Letter

Dec 17, 2024
pulisher
Dec 17, 2024

Franklin Resources Inc. Sells 144,114 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace

Dec 17, 2024
pulisher
Dec 17, 2024

Neurocrine’s First New CAH Treatment in 70 Years Gets FDA Approval - geneonline

Dec 17, 2024
pulisher
Dec 16, 2024

Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - MedCity News

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - Citeline News & Insights

Dec 16, 2024
pulisher
Dec 16, 2024

Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug - Yahoo! Voices

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Trading 5% HigherHere's What Happened - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences rises on FDA nod for CAH drug By Investing.com - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences rises on FDA nod for CAH drug - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Receives "Outperform" Rating from William Blair - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

FDA clears Neurocrine drug for rare adrenal disorder - pharmaphorum

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Benzinga

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Given Outperform Rating at Wedbush - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Goldman Sachs lifts Neurocrine Bio shares target, buy rating on FDA approval - Investing.com Canada

Dec 16, 2024
pulisher
Dec 16, 2024

Launch complexities temper expectations for Neurocrine Bio stock, says BMO Capital - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Geode Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

(NBIX) Technical Data - Stock Traders Daily

Dec 16, 2024
pulisher
Dec 15, 2024

Public Employees Retirement System of Ohio Sells 6,046 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLC - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

Neurocrine wins FDA approval for CAH therapy - MSN

Dec 15, 2024
pulisher
Dec 14, 2024

Neurocrine wins FDA approval for CAH therapy (NBIX:NASDAQ) - Seeking Alpha

Dec 14, 2024
pulisher
Dec 13, 2024

Neurocrine Biosciences to Participate at Investor Conferences in December - The Eastern Progress Online

Dec 13, 2024
pulisher
Dec 13, 2024

US FDA approves Neurocrine Biosciences’ genetic disorder drug - 1470 & 100.3 WMBD

Dec 13, 2024
pulisher
Dec 13, 2024

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia - Longview News-Journal

Dec 13, 2024
pulisher
Dec 13, 2024

US FDA approves Neurocrine Biosciences' genetic disorder drug - Reuters.com

Dec 13, 2024
pulisher
Dec 13, 2024

Virtu Financial LLC Invests $1.99 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

Tri Ri Asset Management Corp Acquires New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

4,191 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by EP Wealth Advisors LLC - MarketBeat

Dec 13, 2024
pulisher
Dec 12, 2024

aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

Neurocrine Biosciences' SWOT analysis: stock faces mixed pipeline results, regulatory challenges - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Tri Ri Asset Management Corp Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 12, 2024
pulisher
Dec 11, 2024

Vestcor Inc Trims Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 11, 2024

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Neurocrine Biosciences Inc Azioni (NBIX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Delaet Ingrid
Chief Regulatory Officer
Dec 17 '24
Sale
135.00
1,091
147,285
2,507
drug_manufacturers_specialty_generic RDY
$15.37
price up icon 1.65%
$12.52
price up icon 3.22%
$83.45
price down icon 0.82%
$89.28
price down icon 2.89%
$11.63
price down icon 1.61%
Capitalizzazione:     |  Volume (24 ore):